Does atrial fibrillation affect plasma endothelin level?

Cardiology Journal

Volumn 17, Issue 5, 2010, Pages 471-476

  Wozakowska KapŁon, Beata ^a,b   Bartkowiak, RadosŁaw ^a   Janiszewska, Grazyna ^c   Grabowska, Urszula ^a  

^a Swietokrzyskie Centre of Cardiology   (Poland)

^b University of Humanities and Science   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Atrial fibrillation; Cardioversion; Endothelin

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVERSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; HYPERTENSION; MALE; PROGNOSIS; PROTEIN BLOOD LEVEL; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; VENTRICULAR FUNCTION, LEFT;

EID: 77957979356     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Byrne M, Kaye DM, Power J. The synergism between atrial fibrillation and heart failure. J Card Fail, 2008; 14: 320-326.
2. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J, 2000; 21: 614-632.
3. Fuster V, Rydén LE, Cannom DS et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guide-lines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J, 2006; 27: 1979-2030.
4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980; 288: 373-376.
5. Masson S, Latini R, Anand IS et al.; Val-HeFT Investigators. Val-HeFT investigators. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail, 2006; 12: 375-380.
6. Luscher TF, Enseleit F, Pacher R et al. Heart Failure ET(A) Receptor Blockade Trial. Hemodynamic and neurohumoral effects of selective endothelin A [ET(A)] receptor blockade in chronic heart failure: The Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation, 2002; 106: 2666-2672.
7. Tuinenburg AE, Van Veldhuisen DJ, Boomsma F, Van Den Berg MP, De Kam PJ, Crijns HJ. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol, 1998; 81: 1207-1210.
8. Masson S, Gorini M, Salio M, Lucci D, Latini R, Maggioni AP. Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators. Ital Heart J, 2000; 1: 282-288.
9. Takahashi N, Ishibashi Y, Shimada T et al. Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail, 2001; 7: 45-54.
10. Roldán V, Marín F, Blann AD et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J, 2003; 24: 1373-1380.
11. Saetrum Opgaard O, Adner M, Peters TH et al. Endocardial expression and functional characterization of endothelin-1. Mol Cell Biochem, 2001; 224: 151-158.
12. Brundel BJ, Van Gelder IC, Tuinenburg AE et al. Endothelin system in human persistent and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol, 2001; 12: 737-742.
13. Goette A, Arndt M, Röcken C et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation, 2000; 101: 2678-2681.
14. Potaczek DP, Sanak M. Endothelin-biosynthesis, function and role in cardiovascular diseases. Pol Arch Med Wewn, 2002; 108: 703-714.
15. Lauer MR, Gunn MD, Clusin WT. Endothelin activates voltage-dependent Ca2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes. J Physiol, 1992; 448: 729-747.
16. Matsumoto Y, Aihara H, Yamauchi-Kohno R et al. Long-term endothelin A receptor blockade inhibits electrical remodeling in cardiomyopathic hamsters. Circulation, 2002; 106: 613-619.
17. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res, 1999; 43: 300-307.
18. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endo-thelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol, 2001; 38 (suppl. 2): S49-S52.
19. Mangiafico RA, Malatino LS, Spada RS et al. Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb. Int Angiol, 2000; 19: 14-17.
20. Letizia C, Cerci S, De Toma G et al. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hyper- tension. J Hum Hypertens, 1997; 11: 447-451.
21. Dézsi CA, Szûcs A, Szûcs G et al. Short-term effect of rate control on plasma endothelin levels of patients with tachyarrhythmias. Exp Biol Med, 2006; 231: 852-856.
22. Marín F, Roldán V, Climent VE et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart, 2004; 90: 1162-1166.
23. Vojácek J, Kolár J, Lisý O et al. Time course of endothelin-1 plasma level in patients with acute coronary syndromes. Cardiology, 1999; 91: 114-118.
24. Zuk-Popiołek I, Flak Z, Francuz T, Tendera M. Plasma endothe- lin-1 in patients with stable or unstable angina. Kardiol Pol, 2003; 58: 429-437.
25. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol, 1989; 63: 193-197.
26. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol, 1989; 63: 1065-1068.
27. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol, 1991; 68: 41-46.
28. De Piccoli B, Rigo F, Ragazzo M, Zuin G, Martino A, Raviele A. Transthoracic and transesophageal echocardiographic indices predictive of sinus rhythm maintenance after cardioversion of atrial fibrillation: An echocardiographic study during direct current shock. Echocardiography, 2001; 18: 545-552.
29. Okçün B, Yigit Z, Küçükoglu MS et al. Predictors for maintenance of sinus rhythm after cardioversion in patients with non-valvular atrial fibrillation. Echocardiography, 2002; 19: 351-357.
30. Van Beneden R, Gurné O, Selvais PL, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in pre- dicting survival in severe congestive heart failure: A 7-year follow-up study. J Card Fail, 2004; 10: 490-495.